http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 07:30:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html <p>Veradermics, Incorporated (NYSE: MANE) presented data from a subgroup analysis of its Phase 2/3 Study '302' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in male patients with mild-to-moderate pattern hair loss, according to a company statement.</p> <p>The data were shared in a poster presentation on July 16, 2026, and in an oral presentation on July 17, 2026, at the 2026 American Academy of Dermatology Innovation Academy in New York City. The oral presentation was delivered by Maria Hordinsky, MD, FAAD, professor and vice chair of research in the Department of Dermatology at the University of Minnesota Twin Cities.</p> <p>Study '302' is http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html Fri, 17 Jul 2026 07:30:24 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html <p>Veradermics, Incorporated (NYSE: MANE) presented data from a subgroup analysis of its Phase 2/3 Study '302' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in male patients with mild-to-moderate pattern hair loss, according to a company statement.</p> <p>The data were shared in a poster presentation on July 16, 2026, and in an oral presentation on July 17, 2026, at the 2026 American Academy of Dermatology Innovation Academy in New York City. The oral presentation was delivered by Maria Hordinsky, MD, FAAD, professor and vice chair of research in the Department of Dermatology at the University of Minnesota Twin Cities.</p> <p>Study '302' is http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html Fri, 17 Jul 2026 07:30:24 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html <p>Veradermics, Incorporated (NYSE: MANE) presented data from a subgroup analysis of its Phase 2/3 Study '302' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in male patients with mild-to-moderate pattern hair loss, according to a company statement.</p> <p>The data were shared in a poster presentation on July 16, 2026, and in an oral presentation on July 17, 2026, at the 2026 American Academy of Dermatology Innovation Academy in New York City. The oral presentation was delivered by Maria Hordinsky, MD, FAAD, professor and vice chair of research in the Department of Dermatology at the University of Minnesota Twin Cities.</p> <p>Study '302' is http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html Fri, 17 Jul 2026 07:30:24 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html <p>Veradermics, Incorporated (NYSE: MANE) presented data from a subgroup analysis of its Phase 2/3 Study '302' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in male patients with mild-to-moderate pattern hair loss, according to a company statement.</p> <p>The data were shared in a poster presentation on July 16, 2026, and in an oral presentation on July 17, 2026, at the 2026 American Academy of Dermatology Innovation Academy in New York City. The oral presentation was delivered by Maria Hordinsky, MD, FAAD, professor and vice chair of research in the Department of Dermatology at the University of Minnesota Twin Cities.</p> <p>Study '302' is http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html Fri, 17 Jul 2026 07:30:24 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html <p>Veradermics, Incorporated (NYSE: MANE) presented data from a subgroup analysis of its Phase 2/3 Study '302' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in male patients with mild-to-moderate pattern hair loss, according to a company statement.</p> <p>The data were shared in a poster presentation on July 16, 2026, and in an oral presentation on July 17, 2026, at the 2026 American Academy of Dermatology Innovation Academy in New York City. The oral presentation was delivered by Maria Hordinsky, MD, FAAD, professor and vice chair of research in the Department of Dermatology at the University of Minnesota Twin Cities.</p> <p>Study '302' is http://www.streetinsider.com/FDA/Veradermics+presents+Phase+23+hair+loss+drug+data+at+AAD+meeting/26781921.html Fri, 17 Jul 2026 07:30:24 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Press+Releases/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. </p><p> Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, http://www.streetinsider.com/Business+Wire/Veradermics+Announces+Presentations+of+Data+from+a+Subgroup+Analysis+of+Phase+23+Study+%E2%80%98302%E2%80%99+in+Males+with+Pattern+Hair+Loss+at+2026+American+Academy+of+Dermatology+Innovation+Academy/26781917.html Fri, 17 Jul 2026 07:30:00 -0400 A.36419058 A.50216724 MANE O.28983125 O.38675772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradermics%2C+Inc++++++++++For%3A+Jul+15/26771625.html si-local-file:///var/storage/secattach/20260715/26771625.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Veradermics%2C+Inc++++++++++For%3A+Jul+15/26771625.html Wed, 15 Jul 2026 08:55:00 -0400 MANE http://www.streetinsider.com/FDA/Veradermics+reports+positive+Phase+2+results+for+oral+hair+loss+drug/26770667.html <p>Veradermics, Incorporated (NYSE: MANE) announced positive topline results from its Phase 2 clinical trial, Study 207, evaluating VDPHL01, an investigational extended-release oral minoxidil tablet, in females with mild-to-moderate pattern hair loss.</p> <p>In the open-label study, 28 female participants received either VDPHL01 4.5mg once daily or 4.5mg twice daily for six months. Participants in the once-daily arm showed a mean increase in non-vellus target area hair count of 22.7 hairs/cm², while the twice-daily arm showed 23.3 hairs/cm² at month six.</p> <p>On a patient-reported outcome scale, 88.9% of once-daily participants and 90.0% of twice-daily participants reported "improved" or "much improved" hair coverage at month http://www.streetinsider.com/FDA/Veradermics+reports+positive+Phase+2+results+for+oral+hair+loss+drug/26770667.html Wed, 15 Jul 2026 07:00:18 -0400 MANE http://www.streetinsider.com/Press+Releases/Veradermics%E2%80%99+Oral+VDPHL01+Delivers+Positive+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+in+Female+Pattern+Hair+Loss+Ahead+of+Upcoming+Phase+23+Study+%E2%80%98306%E2%80%99+Readout/26770643.html <p class="bwalignc"> <i>VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6</i> </p><p class="bwalignc"> <i>Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively</i> </p><p class="bwalignc"> <i>VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally http://www.streetinsider.com/Press+Releases/Veradermics%E2%80%99+Oral+VDPHL01+Delivers+Positive+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+in+Female+Pattern+Hair+Loss+Ahead+of+Upcoming+Phase+23+Study+%E2%80%98306%E2%80%99+Readout/26770643.html Wed, 15 Jul 2026 07:00:00 -0400 MANE http://www.streetinsider.com/Business+Wire/Veradermics%E2%80%99+Oral+VDPHL01+Delivers+Positive+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+in+Female+Pattern+Hair+Loss+Ahead+of+Upcoming+Phase+23+Study+%E2%80%98306%E2%80%99+Readout/26770643.html <p class="bwalignc"> <i>VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6</i> </p><p class="bwalignc"> <i>Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively</i> </p><p class="bwalignc"> <i>VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally http://www.streetinsider.com/Business+Wire/Veradermics%E2%80%99+Oral+VDPHL01+Delivers+Positive+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+in+Female+Pattern+Hair+Loss+Ahead+of+Upcoming+Phase+23+Study+%E2%80%98306%E2%80%99+Readout/26770643.html Wed, 15 Jul 2026 07:00:00 -0400 MANE http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Veradermics+%28MANE%29+at+Buy/26769649.html <p>B.Riley analyst Mayank Mamtani initiates coverage on Veradermics (NYSE: MANE) with a Buy rating and a price target of $170.00.</p><p>The analyst comments: “We are initiating coverage of dermatology and aesthetics specialist Veradermics, Incorporated (MANE) with a Buy rating and a 12-month price target of $170/share. We view lead asset VDPHL01, a proprietary extended-release (ER) oral minoxidil, as a substantially de-risked path to the first FDA-approved oral pill for pattern hair loss (PHL) in nearly 30 years in men and the first-ever approved oral therapy in women. The mechanism engages validated hair biology, i.e., minoxidil, converted by follicular sulfotransferase (SULT1A1) to http://www.streetinsider.com/New+Coverage/B.Riley+Starts+Veradermics+%28MANE%29+at+Buy/26769649.html Wed, 15 Jul 2026 02:14:04 -0400 MANE http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Veradermics+%28MANE%29+at+Buy/26769649.html <p>B.Riley analyst Mayank Mamtani initiates coverage on Veradermics (NYSE: MANE) with a Buy rating and a price target of $170.00.</p><p>The analyst comments: “We are initiating coverage of dermatology and aesthetics specialist Veradermics, Incorporated (MANE) with a Buy rating and a 12-month price target of $170/share. We view lead asset VDPHL01, a proprietary extended-release (ER) oral minoxidil, as a substantially de-risked path to the first FDA-approved oral pill for pattern hair loss (PHL) in nearly 30 years in men and the first-ever approved oral therapy in women. The mechanism engages validated hair biology, i.e., minoxidil, converted by follicular sulfotransferase (SULT1A1) to http://www.streetinsider.com/Analyst+Comments/B.Riley+Starts+Veradermics+%28MANE%29+at+Buy/26769649.html Wed, 15 Jul 2026 02:14:04 -0400 MANE http://www.streetinsider.com/FDA/Veradermics+to+host+call+on+Phase+2+hair+loss+drug+trial+results/26769358.html <p>Veradermics, Incorporated (NYSE: MANE) announced it will host an investor call and live webcast on July 15, 2026, at 8:00 a.m. ET to review results from the female treatment arms of its Phase 2 open-label Study '207' clinical trial.</p> <p>The study evaluated VDPHL01, the company's proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss.</p> <p>VDPHL01 is currently in Phase 3 development and uses an extended-release gel matrix formulation designed to deliver a steady release of minoxidil. According to the company, the formulation is intended to avoid the high peak concentrations associated with immediate-release oral minoxidil.</p> <p>Pattern hair loss, http://www.streetinsider.com/FDA/Veradermics+to+host+call+on+Phase+2+hair+loss+drug+trial+results/26769358.html Tue, 14 Jul 2026 18:54:13 -0400 MANE http://www.streetinsider.com/Press+Releases/Veradermics+to+Hold+Conference+Call+to+Discuss+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+of+VDPHL01+in+Females+with+Mild-to-Moderate+Pattern+Hair+Loss/26769357.html <p class="bwalignc"> <i>Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. </p><p> <b>Webcast Details: <br /></b><b>Time:</b> Wednesday, July 15, 2026 at 8:00 a.m. ET. <br http://www.streetinsider.com/Press+Releases/Veradermics+to+Hold+Conference+Call+to+Discuss+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+of+VDPHL01+in+Females+with+Mild-to-Moderate+Pattern+Hair+Loss/26769357.html Tue, 14 Jul 2026 18:54:00 -0400 MANE http://www.streetinsider.com/Business+Wire/Veradermics+to+Hold+Conference+Call+to+Discuss+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+of+VDPHL01+in+Females+with+Mild-to-Moderate+Pattern+Hair+Loss/26769357.html <p class="bwalignc"> <i>Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. </p><p> <b>Webcast Details: <br /></b><b>Time:</b> Wednesday, July 15, 2026 at 8:00 a.m. ET. <br http://www.streetinsider.com/Business+Wire/Veradermics+to+Hold+Conference+Call+to+Discuss+Study+%E2%80%98207%E2%80%99+Phase+2+Clinical+Trial+Results+of+VDPHL01+in+Females+with+Mild-to-Moderate+Pattern+Hair+Loss/26769357.html Tue, 14 Jul 2026 18:54:00 -0400 MANE http://www.streetinsider.com/Analyst+Comments/Veradermics+%28MANE%29+Reiterated+at+Overweight+by++Cantor+Fitzgerald+After+Investor+Dinner/26688235.html <p>Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Veradermics (NYSE: MANE).</p><p>The analyst commented, "We hosted Veradermics' CEO, Reid Waldman, for a well-attended investor dinner in NYC yesterday (06/23). Following the positive Phase 3 readout in male pattern hair loss (PHL), which exceeded expectations (LINK to note), investor focus has shifted to the female PHL opportunity ahead of the upcoming P2 readout and the P3 female PHL readout next year. During the dinner, we also discussed several other topics, including the commercial opportunity, marketing strategy, IP, compounding, and potential overlap with the obesity market."</p><p>For an analyst ratings summary and http://www.streetinsider.com/Analyst+Comments/Veradermics+%28MANE%29+Reiterated+at+Overweight+by++Cantor+Fitzgerald+After+Investor+Dinner/26688235.html Thu, 25 Jun 2026 07:25:46 -0400 MANE